IHSS

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Retrieved on: 
Tuesday, March 26, 2024
Brain, Disease, Somnolence, Appetite, Partnership, Headache, Visual analogue scale, Patient, Insomnia, EDS, Anxiety, SDX, Doctor of Philosophy, Epworth Sleepiness Scale, Nausea, Clinical trial, Therapy, Safety, Narcolepsy, ESS, IHSS, Idiopathic hypersomnia, Clouding of consciousness, BFS, Food, Pharmaceutical industry

CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). This proof-of-concept study was not powered to demonstrate statistical significance.   The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.

Key Points: 
  • CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial ( NCT05668754 ) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).
  • The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.
  • The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.
  • The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.

Free Training Programs for San Bernardino County Caregivers Address Need for Specialized Skills on Alzheimer's Care and Climate-Related Emergency Preparedness

Retrieved on: 
Thursday, January 18, 2024
Learning, Essential, Caregiver, Research, UC, Policy, SAN, Advisory Committee, RCT, Partnership, Economics, Curriculum, CCA, University, Business, Disease, MIT, Climate change, High Road, IHSS, Workforce, Hallucination, Residential care

SAN BERNARDINO, Calif., Jan. 17, 2024 /PRNewswire/ -- Free training courses are launching this January for caregivers in San Bernardino County.

Key Points: 
  • SAN BERNARDINO, Calif., Jan. 17, 2024 /PRNewswire/ -- Free training courses are launching this January for caregivers in San Bernardino County.
  • Caregivers can enroll in one of three programs: IHSS Essentials, Alzheimer's Disease and Related Dementia (ADRD), and Caregiver Resiliency / Emergency Preparedness.
  • The Caregiver Resiliency course will help caregivers with climate-related emergency preparedness and response and how to recover from post-disaster trauma.
  • "It is important for in-home caregivers to have training programs available so we can provide quality care.

$5 Million Grant to San Francisco Nonprofit Homebridge Aims to Remove Language Barriers for Home Care Workers

Retrieved on: 
Wednesday, January 17, 2024
Employment, Workforce, SAN, Partnership, Curriculum, VESL, Innovation, Language, Communication, Workforce development, IHSS, Vocabulary, Nursing

SAN FRANCISCO, Jan. 17, 2024 /PRNewswire/ -- San Francisco-based Homebridge - California's only nonprofit dedicated to providing both direct in-home supportive services and workforce training to home care providers - has received a two-year, $5 million grant to develop an immersive, on-the-job English language training program for 150 new in-home care providers in San Francisco. The vocational English as a Second Language Home Care Immersion Training Program funded by the California Workforce Development Board, will provide paid Vocational English as a Second Language (VESL) home care training with ongoing language support to strong job candidates whose native language is other than English.

Key Points: 
  • SAN FRANCISCO, Jan. 17, 2024 /PRNewswire/ -- San Francisco-based Homebridge - California's only nonprofit dedicated to providing both direct in-home supportive services and workforce training to home care providers - has received a two-year, $5 million grant to develop an immersive, on-the-job English language training program for 150 new in-home care providers in San Francisco.
  • This career advancement program is funded through an ongoing partnership with the San Francisco Office of Economic and Workforce Development.
  • Past programs provided traditional language courses for employees with limited English, but did not have specific home care language training tied to on-the-job language and skill development.
  • "It will open the door for many more caring individuals in the San Francisco region to join the home care workforce."

Center for Caregiver Advancement Receives $10 Million Grant to Provide Free Training for Caregivers in San Bernardino County

Retrieved on: 
Thursday, May 18, 2023
San Francisco, Workforce, Learning, Pollution, State, IHSS, Partnership, Prevalence, Alzheimer's disease, California Labor and Workforce Development Agency, Disease, Disability, Public, Curriculum, Policy, Abdul Latif Jameel Poverty Action Lab, RCT, University of California, San Francisco, Dignity, CCA, Research, MIT, Respect, Climate change, UC, Access, Growth, Labour, Caregiver, Massachusetts Institute of Technology, Residential care, Nursing

SAN BERNARDINO, Calif., May 18, 2023 /PRNewswire/ -- The Center for Caregiver Advancement (CCA) has been awarded a $10 million grant from the California Workforce Development Board (CWDB) and the Labor and Workforce Development Agency to bring its caregiver training programs to In-Home Supportive Services (IHSS) providers in San Bernardino County. The grant is part of CWDB's HRTP Resilient Workforce Fund.

Key Points: 
  • It will help us provide essential training and resources to caregivers in San Bernardino County, improving both quality of care for consumers and developing specialized skills for workers.
  • Access to CCA's specialized training programs is critical to support older adults and people with disabilities in San Bernardino County.
  • CCA has offered the Alzheimer's care training in Alameda County since 2020, and has started offering it in Los Angeles County this spring.
  • Over 70% of San Bernardino County census tracts have high levels of pollution and are considered disadvantaged areas, according to the CalEnviroScreen index.

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Epilepsy, Cognition, Abstract, LGS, Idiopathic disease, IHSS, Prevalence, MB, Sodium oxybate, Magnesium, AAN, DSM-IV codes, SEGUE, Clinical trial, Trial of the century, Narcolepsy, American Academy, ARISE, DS, Calcium, Hypertension, ESS, ET, Dravet syndrome, Patient, Risk, Epworth Sleepiness Scale, Lennox–Gastaut syndrome, MRCPCH, Neurology, Jazz Pharmaceuticals, Cannabidiol, Sleep, Potassium, Function (mathematics), Idiopathic hypersomnia, Treatment, Total, Caregiver, Safety, Pharmaceutical industry, Nightclub, Xywav

DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.

Key Points: 
  • Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders
    DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.
  • "Jazz has long been at the forefront of providing novel therapies and support for patients living with serious neurologic conditions.
  • Highlights at the 2023 AAN Annual Meeting include:
    Three posters demonstrating the impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, on narcolepsy patients.
  • Two oral presentations of retrospective analyses of U.S. healthcare claims that estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in adult and pediatric patients.

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Epilepsy, Cognition, Abstract, LGS, Idiopathic disease, IHSS, Prevalence, MB, Sodium oxybate, Magnesium, AAN, DSM-IV codes, SEGUE, Clinical trial, Trial of the century, Narcolepsy, American Academy, ARISE, DS, Calcium, Hypertension, ESS, ET, Dravet syndrome, Patient, Risk, Epworth Sleepiness Scale, Lennox–Gastaut syndrome, MRCPCH, Neurology, Jazz Pharmaceuticals, Cannabidiol, Sleep, Potassium, Function (mathematics), Idiopathic hypersomnia, Treatment, Total, Caregiver, Safety, Pharmaceutical industry, Nightclub, Xywav

DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.

Key Points: 
  • Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders
    DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.
  • "Jazz has long been at the forefront of providing novel therapies and support for patients living with serious neurologic conditions.
  • Highlights at the 2023 AAN Annual Meeting include:
    Three posters demonstrating the impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, on narcolepsy patients.
  • Two oral presentations of retrospective analyses of U.S. healthcare claims that estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in adult and pediatric patients.

Center for Caregiver Advancement Addresses Urgent Need for Caregiver Training Through Career Pathways Program

Retrieved on: 
Wednesday, February 8, 2023
Caregiver, Woman, Ageing, CCA, Traumatic brain injury, Social services, Language, Workforce, California Department, Diabetes, Career Pathways, IHSS, Movement, SEIU, Curriculum, Knowledge, California Department of Social Services, Senate, Dementia, LOS, Nursing, Residential care, Alzheimer's disease

LOS ANGELES, Feb. 8, 2023 /PRNewswire/ -- Responding to the urgent need for a highly trained workforce that will take care of California's aging and disabled population, caregivers are signing up by the thousands for the free training offered by the Center for Caregiver Advancement (CCA) through the In-Home Supportive Services (IHSS) Career Pathways Program. The program is part of the state's Master Plan for Aging roadmap, which includes evidence-based, specialized caregiver training as one of its top priorities in the next two years.

Key Points: 
  • The program is part of the state's Master Plan for Aging roadmap, which includes evidence-based, specialized caregiver training as one of its top priorities in the next two years.
  • The curriculum for the Career Pathways Program is based on CCA's existing training on Alzheimer's and dementia care (IHSS+ ADRD), emergency preparedness and community resilience (Caregiver Resiliency Teams), and basic skills (IHSS+).
  • The Career Pathways Program will bring advancement opportunities to the workforce, which will help attract and retain workers."
  • That advocacy work led to the inclusion of $200 million in California's Senate Bill 172 for the IHSS Career Pathways Program.

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

Retrieved on: 
Wednesday, December 21, 2022
ESS, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Orphan, Clinical Global Impression, Glycogen storage disease, KMPH, CNS, IHSS, Disease, Idiopathic hypersomnia, Patient, Safety, Somnolence, FDA, Therapy, IH, SDX, Neurodegeneration, Pharmaceutical industry, Medical imaging

CELEBRATION, Fla., Dec. 21, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare CNS, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the initiation of a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder. KP1077 is comprised solely of serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate. SDX was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH.

Key Points: 
  • KP1077 is comprised solely of serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate.
  • SDX was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH.
  • The Phase 2 clinical trial is a double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing, multi-center study evaluating the efficacy and safety of KP1077 for the treatment of IH.
  • KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.

San Francisco-Based Homebridge Receives $16.2 Million Grant to Strengthen California's Caregiving Workforce

Retrieved on: 
Thursday, October 13, 2022
DAS, SAN, Caregiver, California Department of Social Services, The Public Authority for Applied Education and Training, MPA, CDSS, Social services, California Department, Education, PHI, IHSS, Program, Workforce, CSH, Supportive housing, CAPA, San Francisco Bay Area, Partnership, Knowledge, Goal, CICA, San Francisco Department of Public Health, Association, WPCS, Corporation, City, Homebridge Financial Services, Disability, Leadership, Medicine, Management

SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Homebridge, a San Francisco based organization dedicated to quality in-home supportive services, has received a state grant of up to $16.2 million to strengthen California's caregiving workforce through the In-Home Supportive Services (IHSS) Career Pathways Program. The program, set to launch this month, will provide a broad array of training and career opportunities to the 550,000 IHSS home care providers who serve more than 650,000 residents statewide.

Key Points: 
  • IHSS workers comprise a large portion of California's direct care workforce which currently outnumbers every single occupation in California.
  • The plan aims to strengthen the direct care workforce and create one million high quality direct care jobs by 2031.
  • About Homebridge : Homebridge is California's only nonprofit dedicated to providing direct IHSS services and IHSS workforce training.
  • Homebridge care provides personal and intensive home care services that bridge the gap between healthcare and social services delivery.

The Bliss Group Expands Senior Leadership Team to Match Industry-Leading Growth

Retrieved on: 
Wednesday, October 5, 2022
Media, Social Media, Professional Services, Blogging, Other Communications, Digital Marketing, Other Professional Services, Public Relations, Investor Relations, Marketing, Advertising, Communications, Content Marketing, HR, Insurance, Medicaid, 100,000, Provisions of the Affordable Care Act, Growth, Politics, Public relations, Organization, Policy, ESG, Risk, NASDAQ, B2C, New York Life Insurance Company, IHSS, Publication, PR, Retirement, Investment, Senior, Technology, Rural Health Workforce and The Patient Protection and Affordable Care Act, Marketing, RIMS, Care Act 2014, Black, CEO, NASDAQ OMX, Awareness, FCS, Advertising, Powers, Â, SEIU, Consultant, Leadership, Management, Bliss

Strong growth requires strong leaders, which is why were thrilled to announce this group of promotions, said Bob Pearson, CEO of The Bliss Group.

Key Points: 
  • Strong growth requires strong leaders, which is why were thrilled to announce this group of promotions, said Bob Pearson, CEO of The Bliss Group.
  • The Bliss Group now consists of 90 professionals across healthcare, technology, financial, and business and professional services.
  • It has been incredible to witness the growth of these five talented professionals at Bliss, stated Cortney Stapleton, Managing Partner at The Bliss Group.
  • The contributions of our Senior Leadership Team set us up to succeed, create an outstanding workplace culture and deliver world-class results.